Abstract 4734
Background
Mutations in breast cancer susceptibility gene 1 or 2 (BRCA1/2) are risk factors for developing cancer, especially for breast cancer (BC) and ovarian cancer (OC). Recently, European BC guidelines have expanded the eligibility criteria for BRCA1/2 testing. This study assessed BRCA1/2 testing rates in HER2- adult women with ABC in Germany, France, Italy, Spain and UK (EU5).
Methods
Patient (pt) demographics/clinical characteristics were collected from oncologists in EU5 via Adelphi Advanced Breast Cancer Disease Specific Program. Data collected from 2 years (2015 and 2017) were merged across common variables. Differences in pt demographics/characteristics among BRCA1/2 tested/untested pts were analyzed via t-tests and z-tests. BRCA1/2 testing was analyzed via z-tests. Analyses of BRCA1/2 testing rates were stratified by hormone receptor status [hormone receptor positive (HR+)/HER2- or triple negative breast cancer (TNBC)] and HR status by family history (FHx) of BC or OC.
Results
4,876 records were provided by 742 oncologists. The mean age was 63.6 yrs; 75% HR+/HER2-, 23% TNBC, 2% unknown HR status. Compared to BRCA1/2 untested pts, BRCA1/2 tested pts were younger [57.7 vs 65.2 yrs (p<.001)]and had TNBC [35% vs 20% (p<.001)]. Across all EU5 countries, the mean BRCA1/2 testing rate was 21%; France 20%, Germany 30%, Italy 24%, Spain 20%, UK 14%. Lower BRCA1/2 testing was seen among HR+/HER2- vs TNBC pts [18% vs 33% (p<.001)]. Among HR+/HER2- and TNBC pts, higher BRCA1/2 testing rates were observed among women with a known FHx of BC or OC. (Table). Table. BRCA1/2 Testing by HR Status and known FHx of BC or OC.Table: 292P
HR+/HER2- with FHx (n = 321) | HR+/HER2- without FHx (n = 2,953) | TNBC with FHx (n = 178) | TNBC without FHx (n = 789) | |
---|---|---|---|---|
Pts tested, N (%) | 116 (36) | 476 (16) | 99 (56) | 234 (30) |
P value | <.001 | <.001 |
Conclusions
In this analysis of adult women with ABC, both HR+/HER2- and TNBC pts with a known FHx of BC or OC (vs no known FHx) were more likely to receive BRCA1/2 testing but testing rates are still low especially among HR+/HER2- pts. With the broadening of BRCA1/2 testing eligibility criteria in BC guidelines, opportunities exist to increase BRCA1/2 testing in EU5.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Pfizer Inc.
Funding
Pfizer Inc.
Disclosure
M.P. Lux: Honoraria (self), Advisory / Consultancy: Pfizer Inc.; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Lilly; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Genomic Health; Honoraria (self), Advisory / Consultancy: medac; Honoraria (self), Advisory / Consultancy: Grünethal; Honoraria (self), Advisory / Consultancy: Tesaro; Honoraria (self), Advisory / Consultancy: Eisai. A. Niyazov: Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer Inc. All other authors have declared no conflicts of interest.
Resources from the same session
1025 - Liver metastases (LM) from intrahepatic cholangiocarcinoma (iCCA): Outcomes from the European Network for the Study of Cholangiocarcinoma (ENS-CCA) registry and implications on current American Joint Committee on Cancer (AJCC) staging.
Presenter: Angela Lamarca
Session: Poster Display session 2
Resources:
Abstract
5813 - Is MGMT methylation a new therapeutic target for Biliary Tract Cancer?
Presenter: Monica Niger
Session: Poster Display session 2
Resources:
Abstract
5839 - Biliary Tract Cancers in Portuguese families with BRCA gene mutation: a retrospective study.
Presenter: Patricia Pereira
Session: Poster Display session 2
Resources:
Abstract
4338 - Selection of patients with hepatocellular carcinoma for selective internal radiation therapy based on tumour burden and liver function: a post-hoc analysis of the SARAH trial
Presenter: Daniel Palmer
Session: Poster Display session 2
Resources:
Abstract
1700 - Second-line chemotherapy (SLC) in Patients with Advanced Biliary tract and Gallbladder Cancers (ABGC) Prolongs Survival: A Retrospective Population-based Cohort Study
Presenter: Adnan Zaidi
Session: Poster Display session 2
Resources:
Abstract
5562 - Overall survival of patients with hepatocellular carcinoma receiving sorafenib versus selective internal radiation therapy with predicted dosimetry in the SARAH trial
Presenter: Neil Hawkins
Session: Poster Display session 2
Resources:
Abstract
1838 - Multicenter phase II trial of axitinib monotherapy for advanced biliary tract cancer refractory to gemcitabine-based chemotherapy
Presenter: Naohiro Okano
Session: Poster Display session 2
Resources:
Abstract
3641 - Soluble Programmed Death-ligand 1 indicate poor prognosis in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization
Presenter: Xiaolu Ma
Session: Poster Display session 2
Resources:
Abstract
2733 - The Prognostic Nutritional Index (PNI) is an independent predictor of survival in advanced biliary cancers (ABC) receiving first-line chemotherapy (1L).
Presenter: Francesco Caputo
Session: Poster Display session 2
Resources:
Abstract
3773 - Impact of centralisation of national cancer services on patient outcomes for hepatobiliary cancers in Ireland 2000 – 2016
Presenter: David O Reilly
Session: Poster Display session 2
Resources:
Abstract